After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Bullish option flow detected in Novavax (NVAX) with 5,702 calls trading, 1.1x expected, and implied vol increasing almost 10 points to 99.21%.

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

Novavax Inc. closed 60.94% below its 52-week high of $23.86, which the company reached on June 6th.

“2023 was a transition year for Novavax and we have made tremendous progress towards strengthening the financial profile of the company,” Chief Executive John Jacobs said in a press releas ...

Shares of Novavax Inc. NVAX slid 3.46% to $9.22 Friday, on what proved to be an all-around rough trading session for the ...

Any recent changes to analyst estimates for Novavax should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result ...

Shah Capital has fired a broadside at the management team of Novavax, seeking a change in leadership at the vaccine company and the appointment of two handpicked directors to the board.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Novavax shares ...

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the ...